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Laperriere, N. et al. 2 , and we agree entirely that radiation oncology has, and will likely continue to have for many years, a critical role in the treatment of patients with primary brain tumours. In particular, we note the helpful references to newer radiotherapy approaches, such as stereotactic radiosurgery and proton beam therapy, that are advancing the treatment of brain tumours. As noted by Ludmir and colleagues 1 , a substantial portion of our Position Paper 2 is given over to the discussion of radiation oncology.
As stated in our manuscript 2 , this narrative was composed following a series of international, multidisciplinary meetings, hosted by Cancer Research UK, which engaged many individuals involved in brain tumour research and treatment. It is important to note that our manuscript is a Position Paper and not a Meeting Report. Thus, rather than synthesising the entirety of the discussions that took place during these meetings, it reports the opinions of those authors listed on the paper. The discussions held by the committee did indeed engage radiation oncologists as well as individuals in other disciplines; however, other commitments precluded these individuals from partici pating in many of the meetings and in the writing of our Position Paper 2 . Nonetheless, we wish to assure Ludmir and colleagues 1 that the entire brain tumour research and treatment community recognizes and values the importance and contribution of radiation oncology to the management of brain tumours. We very much look forward to continuing our interactions with colleagues in this discipline for the good of all patients with these terrible diseases.
